Cargando…

Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations

The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following proto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanovska, Ana, Wang, Mengyu, Arshaghi, Tarlan Eslami, Shaw, Georgina, Alves, Joel, Byrne, Andrew, Butterworth, Steven, Chandler, Russell, Cuddy, Laura, Dunne, James, Guerin, Shane, Harry, Rob, McAlindan, Aidan, Mullins, Ronan A., Barry, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230578/
https://www.ncbi.nlm.nih.gov/pubmed/35754551
http://dx.doi.org/10.3389/fvets.2022.897150
_version_ 1784735095471472640
author Ivanovska, Ana
Wang, Mengyu
Arshaghi, Tarlan Eslami
Shaw, Georgina
Alves, Joel
Byrne, Andrew
Butterworth, Steven
Chandler, Russell
Cuddy, Laura
Dunne, James
Guerin, Shane
Harry, Rob
McAlindan, Aidan
Mullins, Ronan A.
Barry, Frank
author_facet Ivanovska, Ana
Wang, Mengyu
Arshaghi, Tarlan Eslami
Shaw, Georgina
Alves, Joel
Byrne, Andrew
Butterworth, Steven
Chandler, Russell
Cuddy, Laura
Dunne, James
Guerin, Shane
Harry, Rob
McAlindan, Aidan
Mullins, Ronan A.
Barry, Frank
author_sort Ivanovska, Ana
collection PubMed
description The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following protocols developed for human application), experimental testing in controlled studies and clinical use in veterinary patients. The ability of MSCs to interact with the inflammatory environment through immunomodulatory and paracrine mechanisms makes them a good candidate for treatment of inflammatory musculoskeletal conditions in canine species. Analysis of existing data shows promising results in the treatment of canine hip dysplasia, osteoarthritis and rupture of the cranial cruciate ligament in both sport and companion animals. Despite the absence of clear regulatory frameworks for veterinary advanced therapy medicinal products, there has been an increase in the number of commercial cell-based products that are available for clinical applications, and currently the commercial use of veterinary MSC products has outpaced basic research on characterization of the cell product. In the absence of quality standards for MSCs for use in canine patients, their safety, clinical efficacy and production standards are uncertain, leading to a risk of poor product consistency. To deliver high-quality MSC products for veterinary use in the future, there are critical issues that need to be addressed. By translating standards and strategies applied in human MSC manufacturing to products for veterinary use, in a collaborative effort between stem cell scientists and veterinary researchers and surgeons, we hope to facilitate the development of quality standards. We point out critical issues that need to be addressed, including a much higher level of attention to cell characterization, manufacturing standards and release criteria. We provide a set of recommendations that will contribute to the standardization of cell manufacturing methods and better quality assurance.
format Online
Article
Text
id pubmed-9230578
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92305782022-06-25 Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations Ivanovska, Ana Wang, Mengyu Arshaghi, Tarlan Eslami Shaw, Georgina Alves, Joel Byrne, Andrew Butterworth, Steven Chandler, Russell Cuddy, Laura Dunne, James Guerin, Shane Harry, Rob McAlindan, Aidan Mullins, Ronan A. Barry, Frank Front Vet Sci Veterinary Science The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following protocols developed for human application), experimental testing in controlled studies and clinical use in veterinary patients. The ability of MSCs to interact with the inflammatory environment through immunomodulatory and paracrine mechanisms makes them a good candidate for treatment of inflammatory musculoskeletal conditions in canine species. Analysis of existing data shows promising results in the treatment of canine hip dysplasia, osteoarthritis and rupture of the cranial cruciate ligament in both sport and companion animals. Despite the absence of clear regulatory frameworks for veterinary advanced therapy medicinal products, there has been an increase in the number of commercial cell-based products that are available for clinical applications, and currently the commercial use of veterinary MSC products has outpaced basic research on characterization of the cell product. In the absence of quality standards for MSCs for use in canine patients, their safety, clinical efficacy and production standards are uncertain, leading to a risk of poor product consistency. To deliver high-quality MSC products for veterinary use in the future, there are critical issues that need to be addressed. By translating standards and strategies applied in human MSC manufacturing to products for veterinary use, in a collaborative effort between stem cell scientists and veterinary researchers and surgeons, we hope to facilitate the development of quality standards. We point out critical issues that need to be addressed, including a much higher level of attention to cell characterization, manufacturing standards and release criteria. We provide a set of recommendations that will contribute to the standardization of cell manufacturing methods and better quality assurance. Frontiers Media S.A. 2022-06-10 /pmc/articles/PMC9230578/ /pubmed/35754551 http://dx.doi.org/10.3389/fvets.2022.897150 Text en Copyright © 2022 Ivanovska, Wang, Arshaghi, Shaw, Alves, Byrne, Butterworth, Chandler, Cuddy, Dunne, Guerin, Harry, McAlindan, Mullins and Barry. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Ivanovska, Ana
Wang, Mengyu
Arshaghi, Tarlan Eslami
Shaw, Georgina
Alves, Joel
Byrne, Andrew
Butterworth, Steven
Chandler, Russell
Cuddy, Laura
Dunne, James
Guerin, Shane
Harry, Rob
McAlindan, Aidan
Mullins, Ronan A.
Barry, Frank
Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
title Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
title_full Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
title_fullStr Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
title_full_unstemmed Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
title_short Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
title_sort manufacturing mesenchymal stromal cells for the treatment of osteoarthritis in canine patients: challenges and recommendations
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230578/
https://www.ncbi.nlm.nih.gov/pubmed/35754551
http://dx.doi.org/10.3389/fvets.2022.897150
work_keys_str_mv AT ivanovskaana manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT wangmengyu manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT arshaghitarlaneslami manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT shawgeorgina manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT alvesjoel manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT byrneandrew manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT butterworthsteven manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT chandlerrussell manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT cuddylaura manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT dunnejames manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT guerinshane manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT harryrob manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT mcalindanaidan manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT mullinsronana manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations
AT barryfrank manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations